Ultraviolet A Combined with Narrow-Band Ultraviolet B is an Effective Treatment Modality for Early Folliculotropic Mycosis Fungoides and Early Mycosis Fungoides Refractory to Narrow-Band Ultraviolet B: A Retrospective Cohort Study
Table 2
Adult and pediatric patients with early-stage FMF and non-FMF treated with UVA combined with NBUVB: treatment-related parameters and outcomes.
Response to treatment, FMF patients N = 39
Adult patients N = 25
Patients ≤18 years N = 14
All patients N = 39
ORR# (%)
CR# (%)
PR (%)
Number of treatments to CR, median/mean (range)
Final dose of UVA and NBUVB in the CR group, median (range) J/cm2
ORR# (%)
CR# (%)
PR (%)
Number of treatments to CR, median/mean (range)
Final dose of UVA and NBUVB in the CR group, median (range) J/cm2
ORR (%)
CR (%)
PR (%)
24 (96)
15 (60)
9 (36)
42/46 (20–75)
UVA: 9 (5–12); NBUVB: 2.4 (1.5–2.5)
13 (93)
9(64)
4(29)
57/50 (20–80)
UVA: 11 (10–15); NBUVB: 2 (0.8–2.4)
37 (95)
24 (62)
13 (33)
Response to treatment, non-FMF patients N=12
Adult patients N = 10
Patients ≤18 years N = 2
All patients N = 12
ORR (%)
CR (%)
PR (%)
Number of treatments to CR, median/mean (range)
Final dose of UVA and NBUVB in the CR group, median (range) J/cm2
ORR (%)
CR (%)
PR (%)
Number of treatments to CR
Final dose of UVA and NBUVB in the CR group, J/cm2
ORR (%)
CR (%)
PR (%)
8 (80)
4 (40)
4 (40)
55/57 (40–72)
UVA: 9 (6–15); NBUVB: 2.3 (1.4–2.5)
2 (100)
2 (100)
0
46 and 50 treatments
UVA: 9 in both; NBUVB: 1 and 1.4
10 (83)
6 (50)
4 (33)
CR, complete response; FMF, folliculotropic mycosis fungoides; NBUVB, narrow-band ultraviolet B; ORR, overall response rate; PR, partial response; UVA, ultraviolet A. #No significant differences in the ORR and the CR rate were noted between the adult and the pediatric groups of patients (). No significant difference in the median number of combined UVA and NBUVB treatments, leading to CR, was noted between the adult and the pediatric groups of patients ().
